Hemodialysis patients with coronavirus disease 2019: reduced antibody response

Hiroko Beppu1 · Tatsuya Fukuda2,3 · Tomoko Kawanishi1 · Fumihiko Yasui4 · Minami Toda1 · Hitomi Kimura1 · Yuki Nakamura1 · Yuka Nakamura1 · Kaori Kojima1 · Hina Ogawa1 · Ayumi Ishiwatari1 · Yuiko Kamei1 · Toshie Ogawa1 · Yasutomo Abe1 · Mariko Endo1 · Tomohide Hanawa5 · Rie Mizobuchi5 · Chise Sugita5 · Koh Okamoto5,6 · Shuji Hatakeyama5,7 · Tetsusya Yamada3 · Michinori Kohara4 · Sachiko Wakai1

Received: 27 July 2021 / Accepted: 30 August 2021 / Published online: 6 September 2021
© Japanese Society of Nephrology 2021

Abstract
Background Because patients on maintenance hemodialysis (HD) have an impaired immune response to pathogens, they are at higher risk of severe coronavirus disease 2019 (COVID-19). However, data on antibody production among HD patients with COVID-19 is scarce. Thus, we performed a retrospective cohort study evaluating severe acute respiratory syndrome coronavirus two antibody (SARS-CoV-2) production within 1 month after COVID-19 onset in hospitalized patients on HD.
Methods SARS-CoV-2-specific immunoglobulin (Ig) G levels were quantified using an iFlash 3000 Chemiluminescence Immunoassay analyzer (Shenzhen YHLO Biotech Co., Ltd.) to detect IgG antibodies specific for the S1 subunit of the spike protein (IgG-S1). Propensity score matching was used to balance covariate distribution in HD and non-HD patients. From April 2020 to February 2021, antibody testing was performed on 161 hospitalized patients with symptomatic COVID-19. Of them, 34 HD patients were matched to 68 non-HD patients.
Results After propensity score matching, the median levels of IgG-S1 in the HD patients at 7–13 days after symptom onset were significantly lower than in non-HD patients, especially in those with severe disease. Among all patients, those with severe disease produced lower levels of IgG-S1 at 7–13 days compared with non-severe patients.
Conclusion COVID-19 patients with severe disease, especially those undergoing HD, had lower IgG-S1 production in the second week of the disease. Thus, the increased risk of severe COVID-19 in HD patients may be, in part, due to a slow and reduced antibody response.

Keywords Hemodialysis · Immune response · COVID-19 · Antibody · Severe disease · SARS-CoV-2

Introduction
At the end of 2019, the coronavirus disease 2019 (COVID-19) which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread all over the world, and the World Health Organization declared this outbreak as a public health emergency of international concern [1]. Patients on maintenance hemodialysis (HD) are considered as a highly vulnerable population to COVID-19 infection due to the fact that they have a higher probability of having comorbidities such as diabetes and cardiovascular disease. Indeed, recent studies reported that patients on HD are at high risk of adverse outcomes of COVID-19, and the mortality rates from COVID-19 can reach as high as 20% [2–5]. Patients on HD generally show an impaired immune response to pathogens [6], therefore, inadequate antibody production to SARS-CoV-2 may partially explain the association between HD and poor clinical outcome. However, data on antibody production among COVID-19 patients undergoing HD remain scarce. In this article, we retrospectively evaluated antibody responses to SARS-CoV-2 during the development of symptomatic COVID-19 in patients on HD and those not-on HD.
Materials and methods

Study design and population

This retrospective cohort study evaluated SARS-CoV-2 antibody production within 1 month after symptom onset in adult patients with COVID-19 at Okubo Hospital, Tokyo, Japan. Okubo Hospital falls within the Tokyo Metropolitan public hospital network and is designated to provide inpatient care for COVID-19 patients who do not require high-flow oxygen or intensive care, particularly for patients on maintenance HD. Our study cohort included symptomatic patients with COVID-19 who were tested for anti-SARS-CoV-2 antibodies and compared antibody levels between HD and non-HD patients. Furthermore, we assessed differences in antibody levels according to the disease severity. Severe disease was defined as partial pressure of oxygen/fraction of inspired oxygen (P/F) ratio < 300 or oxygen saturation (SpO2) < 94% during hospitalization, based, in part, on the definition according to the COVID-19 Treatment Guidelines Panel of the United States National Institutes of Health [7]. COVID-19 was diagnosed using a reverse transcription polymerase chain reaction.

Antibody measurement

Frozen and stored serum samples left over after clinical testing were used to measure the concentration of anti-SARS-CoV-2 antibodies using iFlash 3000 chemiluminescence immunoassay analyzer (Shenzhen YHLO Biotech, China). We purchased two kits; the iFlash–SARS-CoV-2 IgG-S1 kit and the iFlash SARS-CoV-2 IgG kit. The iFlash–SARS-CoV-2 IgG-S1 kit detected immunoglobulin (Ig) G specific to the S1 subunit of the spike protein (IgG-S1). The iFlash–SARS-CoV-2 IgG kit detected IgG to the nucleocapsid (N) and spike (S) proteins (IgG). According to the manufacturer’s instructions, results with values ≥ 10 arbitrary units (AU)/mL were considered positive.

Clinical data collection

We obtained data on comorbidities [diabetes mellitus, hypertension, chronic obstructive pulmonary disease (COPD), cardiovascular disease, and cancer history], demographics (age, sex, body mass index, and smoking status), information related to disease severity (SpO2, P/F ratio, and type of oxygen therapy), laboratory test results, and medication (renin–angiotensin–aldosterone system inhibitors, immunosuppressive agents and iron supplementation) from the electronic medical records of each patient. Baseline clinical data were collected on the first day of admission. In patients on HD, laboratory parameters at baseline were determined using the results of blood samples taken before dialysis. Hypertension was diagnosed based on the history in the medical record or current use of antihypertensive medications. Diabetes mellitus was diagnosed based on the history in the medical record, current use of antidiabetic medications, or glycated hemoglobin ≥ 6.5% on admission. COPD was diagnosed based on the history in the medical record or the presence of typical COPD changes on high-resolution computed tomography scans. Cardiovascular disease was diagnosed based on the history of stroke, unstable angina, myocardial infarction, percutaneous coronary intervention, coronary bypass grafting, angioplasty, or major amputation as a result of peripheral arterial disease in the medical record. For the accuracy of clinical outcome data, patients with COVID-19 who developed severe disease necessitating transfer to another hospital for intensive care were tracked to ensure accuracy of the clinical outcome data and to record the mortality rate.

Statistical analysis

Data were presented as mean ± standard deviation, median with interquartile range, or percentage according to data distribution. Categorical variables were compared using the chi-squared test. Differences were analyzed using the t test or Mann–Whitney U test, as appropriate for the data distribution. The propensity score for HD in each patient was calculated using a logistic regression model incorporating covariates (age, sex, body mass index, diabetes mellitus, hypertension, cardiovascular disease, and COPD) to balance covariate distribution between the HD and non-HD patients. Then, we used the propensity scores to perform 1:2 matching between HD and non-HD patients with the nearest neighbor algorithm. p values < 0.05 were considered statistically significant. Statistical analyses were performed using SPSS v21.0 (IBM Corp., Armonk, NY, USA).

Results

Figure 1 shows the study flow chart. Antibody testing was performed on 172 of 225 COVID-19 patients admitted between April 2020 and February 2021. After excluding 11 asymptomatic patients, the final study cohort comprised 161 symptomatic patients (34 on maintenance HD). The causes of end-stage renal disease among the HD patients were diabetes mellitus (n = 11), hypertension (n = 7), glomerular disease (n = 7), autosomal dominant polycystic kidney disease (n = 1), and others or unknown (n = 8). We used propensity score matching to match 34 HD patients to 68 non-HD patients; baseline clinical characteristics, except the prevalence of current smoking, comorbidities,
and specific medications, were comparable between the two groups. Lymphocyte counts (HD: 0.6 × 10⁹ vs. non-HD 1.0 × 10⁹/l, \( p < 0.001 \)) and albumin levels (HD 31 vs. non-HD 36 g/l, \( p = 0.001 \)) were significantly lower in HD patients than non-HD patients. C-reactive protein (HD 2.71 vs. non-HD 3.56 mg/dl) and ferritin (HD 279 vs. non-HD 347 ng/ml) levels were not significant. As for baseline medication, the number of patients receiving iron supplementation was significantly higher in the HD patients than non-HD patients (15 vs. 0%, respectively, \( p = 0.003 \)). The proportion of HD patients who received remdesivir was significantly lower than non-HD patients (0 vs. 19%, respectively, \( p = 0.004 \)), but there was no significant difference in steroid use (64 vs. 50%, respectively, \( p = 0.261 \)) or favipiravir (85 vs. 75%, respectively, \( p = 0.233 \)). The proportion of HD versus non-HD patients who developed the severe disease (13 of 34, 38% vs. 16 of 68, 24%, respectively, \( p = 0.187 \)) and the mortality rate between the two groups (HD 6 of 34, 18% vs. non-HD 7 of 68, 10%, \( p = 0.350 \)) were similar (Table 1).

We used 596 samples obtained from 102 propensity score-matched patients up to 27 days after symptom onset to measure IgG-S1 and IgG concentrations. The median number of antibody measurements during hospitalization was not significantly different between the two groups (HD 5 times vs. non-HD 4 times, \( p = 0.108 \)).

As shown in Fig. 2, in HD patients, the median (interquartile range [IQR]) levels of IgG-S1 at 7–13 days were significantly lower than those in non-HD patients [Fig. 2a, 5.4 (0.7–42.1) vs. 11.7 (1.9–107.4) AU/ml, \( p = 0.032 \)]. In patients with severe COVID-19, the IgG-S1 levels at 7–13 days in HD patients were significantly lower than in non-HD patients [1.5 (0.5–5.2) vs. 5.7 (0.7–38.3) AU/ml, \( p = 0.018 \)]. There was no difference in IgG-S1 levels at 7–13 days between the HD and non-HD patients with non-severe disease [11.7 (1.5–127.0) vs. 18.4 (2.8–117.6) AU/ml, \( p = 0.368 \)]. Regardless of disease severity, strong and similar IgG-S1 antibody responses were observed 14 days after symptom onset in both cohorts. Similar to the kinetics of IgG-S1, the levels of IgG in 7–13 days in the HD patients were significantly lower than those in the non-HD patients [Fig. 2b, 8.8 (1.0–41.7) AU/mL vs. 20.5 (1.4–56.5) AU/mL, \( p = 0.042 \)]. In patients with severe disease, HD patients had a tendency to show lower IgG response than non-HD patients at 7–13 days [1.5 (0.5–8.7) AU/mL vs. 6.9 (0.8–43.1) AU/mL, \( p = 0.101 \)].

Figure 3 illustrates the difference in antibody responses between severe patients and non-severe patients. In both HD and non-HD patients, those with severe disease showed a significantly lower IgG-S1 antibody response at 7–13 days (Fig. 3a). The median (IQR) level of IgG-S1 at 7–13 days for all patients was 3.7 (0.6–34.0) AU/ml in severe patients and 11.7 (1.9–107.4) AU/ml in non-severe patients (\( p = 0.042 \)). IgG levels were consistently lower in severe patients compared with that in non-severe patients throughout the 28 days after symptom onset (Fig. 3b).

**Discussion**

COVID-19 patients who developed severe illness, especially those receiving maintenance HD, had lower IgG-S1 production than non-severe patients during the second week of the disease after symptom onset. The increased risk of severe COVID-19 could be attributed to a slow antibody response to SARS-CoV-2 spike protein. Anti-spike IgG antibodies are significantly correlated with virus-neutralizing antibody titers [8], suggesting a critical role in protection against SARS-CoV-2 infection. Lucas et al. recently reported that deceased COVID-19 patients showed delayed anti-spike IgG production and neutralizing antibody response before the second week after symptom onset compared with discharged patients [9]. This may support our findings that slow IgG-S seroconversion was significantly more frequently observed in patients who developed a severe illness.

To the best of our knowledge, this is the first study showing different IgG-S1 antibody responses between HD and non-HD patients who developed severe illness in the early stage of SARS-CoV-2 infection. The majority of HD patients with COVID-19 have been reported to develop specific antibodies, including IgG, within 1 month after symptom onset [10, 11], which is consistent with our study finding that most patients produced IgG antibodies within 3 weeks after onset, plateauing in the third week after onset. However, we found that IgG-S1 responses were significantly much lower in the second week in the HD patients compared with the non-HD
patients, especially those with severe disease, suggesting that the delayed antibody response partly contributes to worse clinical outcomes in HD patients.

The percentage of patients who smoked in our study was significantly higher among the non-HD patients than among the HD patients. People who smoke have shown decreased production of IgG [12, 13], and therefore the antibody response to SARS-CoV-2 may be impaired in smokers. In fact, a study in individuals who recovered from SARS-CoV-2 infection demonstrated that those who smoked had lower anti–SARS-CoV-2 IgG levels up to 4 months after diagnosis of COVID-19 [14]. However, it is currently unclear whether the antibody response within 1 month after COVID-19 onset is impaired in people who smoke. Therefore, we evaluated the differences in antibody responses between patients who smoked and those who did

| Table 1 | Baseline clinical characteristics, comorbidities, medication, and the clinical outcomes in patients on HD and those not on HD |
| Unmatched patients | Propensity score matched patients | Non-HD group |
|---------------------|----------------------------------|--------------|
|                     | HD-group | Non-HD group |
|                     | n = 59   | n = 34       | n = 68       |
| **Clinical characteristics at baseline** | | | |
| Age, yr             | 52.8 ± 21.3 | 66.3 ± 17.2 | 59.7 ± 22.3 | 0.110 |
| Female sex          | 18 (31)   | 10 (29)      | 25 (37)     | 0.606 |
| Body mass index, kg/m² | 24.0 ± 3.7 (N = 56) | 22.6 ± 4.3 | 23.7 ± 3.7 | 0.143 |
| Current smoker      | 16 (27)   | 9 (26)       | 34 (50)     | 0.004 |
| **Comorbidities**   | | | |
| Diabetes mellitus   | 10 (17)   | 15 (44)      | 25 (37)     | 0.616 |
| Hypertension        | 1 (0)     | 31 (91)      | 64 (94)     | 0.890 |
| COPD                | 4 (7)     | 1 (3)        | 3 (4)       | 1.000 |
| Cardiovascular disease | 0 (0)   | 15 (47)      | 16 (24)     | 0.057 |
| Cancer history      | 6 (10)    | 7 (21)       | 6 (9)       | 0.172 |
| Symptom onset to admission, d | 6.5 ± 3.1 | 5.6 ± 6.8 | 5.9 ± 4.1 | 0.785 |
| **Baseline medications** | | | |
| RAS inhibitors      | 2 (3)     | 15 (44)      | 23 (34)     | 0.452 |
| Immunosuppressive agent | 0 (0)   | 3 (9)        | 2 (3)       | 0.205 |
| Iron supplementation | 0 (0)    | 5 (15)       | 0 (0)       | 0.003 |
| **Laboratory parameters at admission** | | | |
| White blood cells, 10⁹/l | 5.0 (4.0–5.9) | 4.6 (3.5–5.8) | 5.3 (4.1–7.2) | 0.088 |
| Neutrophils, 10⁹/l   | 2.9 (2.4–3.7) | 3.0 (2.2–4.2) | 3.3 (2.4–4.9) | 0.348 |
| Lymphocyte, 10⁹/l    | 1.1 (0.8–1.6) | 0.6 (0.3–1.0) | 1.0 (7.2–1.3) | < 0.001 |
| Albumin, g/l         | 39 (37–43) | 31 (28–34)   | 36 (32–41)  | 0.001 |
| BUN, mg/dl           | 11.5 (9.1–13.8) | 51.3 (39.9–67.4) | 15.1 (11.7–25.0) | < 0.001 |
| Serum creatinine, mg/dl | 0.80 (0.65–0.95) | 9.90 (7.45–13.01) | 0.84 (0.70–1.09) | < 0.001 |
| eGFR, ml/min per 1.73 m² | 80.0 (66.5–88.5) | N/A | 63.8 (48.6–85.0) | N/A |
| C-reactive protein, mg/l | 2.58 (0.59–5.01) | 2.71 (1.10–5.28) | 3.56 (0.96–7.30) | 0.943 |
| Ferritin, µg/l       | 296 (210–586) | 279 (164–564) (N = 33) | 347 (216–665) | 0.074 |
| D-dimer, µg/l        | 0.87 (0.65–1.14) | 1.31 (0.90–2.35) (N = 33) | 0.94 (0.75–1.98) | 0.302 |
| **Adjuvant COVID-19 therapy** | | | |
| Remdesivir           | 7 (12)    | 0 (0)        | 13 (19)     | 0.004 |
| Steroid              | 18 (31)   | 21 (64)      | 34 (50)     | 0.261 |
| Favipiravir          | 37 (63)   | 29 (85)      | 51 (75)     | 0.233 |
| **Clinical outcomes** | | | |
| Severe disease       | 9 (15)    | 13 (38)      | 16 (24)     | 0.187 |
| Death                | 0 (0)     | 6 (18)       | 7 (10)      | 0.350 |

Data are expressed as mean ± standard deviation (SD), median [interquartile range (IQR)], or as number [proportion (%)]

COPD chronic obstructive pulmonary disease, RAS renin–angiotensin–aldosterone system, BUN blood urea nitrogen, eGFR estimated glomerular filtration ratio, COVID-19 coronavirus disease 2019, N/A not applicable

*p value for difference between non-HD and HD group in percent (Chi-square test), means (t test), or medians (Mann–Whitney U test)
Fig. 2 Kinetics of anti-SARS-CoV-2 antibodies in 34 HD patients and 68 non-HD patients. a Kinetics of anti-SARS-CoV-2 IgG-S1. b Kinetics of anti–SARS-CoV-2 IgG. Antibody levels were log2-transformed. Blue lines represent the threshold value for positive. Comparisons of antibody titers in the same time period were performed using the Mann–Whitney U test. *p < 0.05. Abbreviations: HD hemodialysis, IgG-S immunoglobulin G specific for the S1 subunit of the S protein, IgG immunoglobulin G that detected N and S proteins, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

Fig. 3 Kinetics of anti-SARS-CoV-2 antibodies 29 severe patients and 73 non-severe patients. a Kinetics of anti-SARS-CoV-2 IgG-S1. b Kinetics of anti–SARS-CoV-2 IgG. Antibody levels were log2-transformed. Blue lines represent the threshold value for positive. Comparisons of antibody titers in the same time period were performed using the Mann–Whitney U test. *p < 0.05. Abbreviations: HD hemodialysis, IgG-S immunoglobulin G specific to the S1 subunit of the S protein, IgG immunoglobulin G that detected N and S proteins, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
not smoke in both HD and non-HD patients, respectively. As expected, we noted that among the HD patients, IgG-S1 levels at 7–20 days were significantly lower in the smokers than in the nonsmokers (data not shown). However, we found no significant differences in either the IgG-N or IgG-S1 response among non-HD patients. Further studies are warranted to investigate whether smoking affects antibody responses to SARS-CoV-2.

Regarding laboratory parameters at admission, the lymphocyte counts in HD patients were significantly lower than that in non-HD patients on admission. A low lymphocyte count was reported as associated with severe COVID-19 [15]. Thus, reduced antibody production in the early stage of the illness in patients on HD could be associated with severe disease. A randomized clinical trial showed the efficacy of an anti-SARS-CoV-2 monoclonal antibody cocktail for reducing the viral load among outpatients with mild to moderate COVID-19 [16]. Therefore, timely antibody supplementation could decrease the risk of progression to severe disease in high-risk populations, such as HD patients.

Although iFlash–SARS-CoV-2 IgG kit used a combination of both N and S antigens, IgG levels measured by this kit were reported to be strongly correlated with the antibody levels against SARS-CoV-2 N protein [17]. The reason for this was speculated that the magnetic beads were predominantly coated with the N protein, with only a small proportion of S protein. Thus, we considered the iFlash–SARS-CoV-2 IgG kit to mainly detect anti-N IgG antibody and found that not only IgG-S1 but also anti-N IgG antibody might have been reduced in the second week in HD patients compared with non-HD patients. Although a correlation between anti-N IgG antibody levels and a poor clinical outcome has been reported [18], the clinical significance of IgG response to SARS-CoV-2 N protein, especially a delayed one, remains unelucidated.

Our study had several limitations. First, it was a single-centered design, and the sample size was small. Second, because of the wide variety of SARS-CoV-2 assays, our antibody tests for IgG-S1 might not have targeted the same spike protein domain as other studies. Third, we did not assess the neutralizing antibody response. Fourth, although we used propensity score matching, unmeasured confounding variables could have affected the differences in antibody response between HD and non-HD patients.

In conclusion, patients with severe COVID-19, especially those receiving maintenance HD, produced significantly lower IgG-S1 antibody levels than patients with the non-severe disease during the second week after symptom onset. A slow and partially reduced antibody response may explain the increased risk of severe COVID-19 among HD patients.

Acknowledgements The authors would like to thank Dr. Sho Hasegawa (Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine) for advice and comments for designing the study, and Enago (www.enago.jp) for the English language review. We would also like to thank the hospital staff at Okubo Hospital for caring for patients with COVID-19.

Author contributions HB and TF researched data and wrote the manuscript. HB, TF, and HK performed the statistical analyses. FY and MK measured antibodies. HB, TF, TK, MT, FY, KO, SH, MK, and SW contributed to intellectual discussion and reviewed and edited the manuscript. YN, YN, KW, HO, AI, YK, TO, YA, ME, TH, RM, CS, and TY contributed to interpretation of the data. TF is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors reviewed and approved the final manuscript.

Funding This work was supported by the Tokyo Metropolitan Government, Japan, and research and training fee from Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan.

Data availability and material All data were available from the corresponding author upon reasonable request.

Declarations

Conflict of interest The authors have declared that no conflict of interest exist.

Ethical approval This study was conducted in accordance with the principles of the Declaration of Helsinki and with the approval of the ethical committee of Okubo Hospital (No. 2020–11).

Informed consent Written informed consent was waived because of the retrospective design. We provided patients with the opportunity to opt out by displaying an outline of the analysis on the hospital Web site.

References

1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323:709–10.
2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
3. Hsu CM, Weiner DE, Aweh G, Miskulin DC, Manley HJ, Stewart C, et al. COVID-19 Among US dialysis patients: risk factors and outcomes from a national dialysis provider. Am J Kidney Dis. 2021;77:748-756.e1.
4. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakihya V, Hong S, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98:1530–9.
5. Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35:1973–83.
6. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:1526–33.
7. National Institutes of Health. COVID-19 Treatment Guidelines. Clinical Spectrum of SARS-CoV-2 Infection. Accessed at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ on 30 June 2021.
8. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–42.
9. Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat Med. 2021;27:1178–86.
10. Labriola L, Scohy A, Seghers F, Perlot Q, De Greef J, Desmet C, et al. A longitudinal, 3 month serologic assessment of SARS-CoV-2 infections in a Belgian hemodialysis facility. Clin J Am Soc Nephrol. 2021;16:613–4.
11. De Vriese AS, Reinders M. IgG antibody response to SARS-CoV-2 infection and viral RNA persistence in patients on maintenance hemodialysis. Am J Kidney Dis. 2020;76:440–1.
12. Qiu F, Liang CL, Liu H, Zeng YQ, Hou S, Huang S, et al. Impacts of cigarette smoking on immune responsiveness: Up and down or upside down? Oncotarget. 2017;8:268–84.
13. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Mei-jide LM, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008;151:42–50.
14. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383:1724–34.
15. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis. 2020;96:131–5.
16. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as monotherapy or in combination With Etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–44.
17. Kaneko Y, Sugiyama A, Tanaka T, Fukui K, Taguchi A, Nakayama A, et al. The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleocapsid, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. medRxiv. 2021. https://doi.org/10.1101/2021.06.17.21258858.
18. Batra M, Tian R, Zhang C, Clarence E, Sacher CS, Miranda JN, et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep. 2021;11:3455.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Authors and Affiliations

Hiroko Beppu¹ · Tatsuya Fukuda²,³ · Tomoko Kawanishi¹ · Fumihiko Yasui⁴ · Minami Toda¹ · Hitomi Kimura¹ · Yuki Nakamura¹ · Yuka Nakamura¹ · Kaori Kojima¹ · Hina Ogawa¹ · Ayumi Ishiwatari¹ · Yuiko Kamei¹ · Toshie Ogawa¹ · Yasutomo Abe¹ · Mariko Endo¹ · Tomohide Hanawa² · Rie Mizobuchi² · Chise Sugita² · Koh Okamoto²,³ · Shuji Hatakeyama⁵,⁷ · Tetsusya Yamada³ · Michinori Kohara⁴ · Sachiko Wakai¹

Hiroko Beppu
korohipube@gmail.com
Tomoko Kawanishi
tomoko_kawanishi@tokyo-hmt.jp
Fumihiko Yasui
yasui-fm@igakuken.or.jp
Minami Toda
minami_toda@tokyo-hmt.jp
Hitomi Kimura
hitomi_kimura@tokyo-hmt.jp
Yuki Nakamura
yuki_yoshikawa@tokyo-hmt.jp
Yuka Nakamura
yuka_nakamura2@tokyo-hmt.jp
Kaori Kojima
kaori_kojima1@tokyo-hmt.jp
Hina Ogawa
hina_ogawa@tokyo-hmt.jp
Ayumi Ishiwatari
ayumi_ishiwatari@tokyo-hmt.jp
Yuiko Kamei
yuiko_kamei@tokyo-hmt.jp
Toshie Ogawa
toshie_kaga@tokyo-hmt.jp
Yasutomo Abe
yasutomo_abe@tokyo-hmt.jp
Mariko Endo
mariko_endo@tokyo-hmt.jp
Tomohide Hanawa
tomohide_hanawa@tokyo-hmt.jp
Rie Mizobuchi
rie_mizobuchi@tokyo-hmt.jp
Chise Sugita
chise_sugita@tokyo-hmt.jp
Koh Okamoto
kokamoto-ky@umin.ac.jp
Shuji Hatakeyama
shatake-ky@umin.ac.jp
Tetsusya Yamada
tyammem@tmd.ac.jp
Michinori Kohara
kohara-mc@igakuken.or.jp
Sachiko Wakai
sachiko_wakai@tokyo-hmt.jp

¹ Department of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan
² Department of Endocrinology and Metabolism, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan
